Name | CeMMEC1 HCl |
Synonyms | CeMMEC1 cemmecl CeMMEC1 HCl 440662-09-9 CeMMEC1(free base) 4-Isoquinolinecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-1,2-dihydro-2-methyl-1-oxo- |
CAS | 440662-09-9 |
Molecular Formula | C19H16N2O4 |
Molar Mass | 336.34 |
Density | 1.386±0.06 g/cm3(Predicted) |
Boling Point | 590.1±50.0 °C(Predicted) |
pKa | 11.38±0.20(Predicted) |
Storage Condition | -20℃ |
In vitro study | CeMMEC1 is an inhibitor of BRD4, and also has high affinity for TAF1, with an IC 50 of 0.9 μM for TAF1, and a K d of 1.8 μM for TAF1 (2) and slso shows high affinity for the bromodomains of CREBBP, EP300, BRD9. CeMMEC1 (1, 10, 20 μM) decreases the number of THP1 cells in S phase in a dose manner. CeMMEC1 also induces apoptosis. CeMMEC1 in combination with (S)-JQ1 displays potently impaired cell viability than treatment alone. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.973 ml | 14.866 ml | 29.732 ml |
5 mM | 0.595 ml | 2.973 ml | 5.946 ml |
10 mM | 0.297 ml | 1.487 ml | 2.973 ml |
5 mM | 0.059 ml | 0.297 ml | 0.595 ml |
biological activity | CeMMEC1 is an inhibitor of BRD4 and has high affinity for TAF1, with IC50 value of 0.9 μM for TAF1 and Kd value of 1.8 μM for TAF1 (2). |
target | Kd: 1.8 μM (TAF1 (2)) IC50: 0.9 μM (TAF1) |
in vitro study | CeMMEC1 is an inhibitor of BRD4, and also has high affinity for TAF1, with an IC 50 of 0.9 μ m for TAF1, and a K d of 1.8 μ m for TAF1 (2) and slso shows high affinity for the bromodomains of CREBBP, EP300, BRD9. CeMMEC1 (1, 10, 20 μ m) decreases the number of THP1 cells in S phase in a dose manner. CeMMEC1 also induces apoptosis. CeMMEC1 in combination with (S)-JQ1 displays potently impaired cell viability than treatment alone. |